Seattle, WA, United States of America

Cecile Morales

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Cecile Morales

Introduction

Cecile Morales is a prominent inventor based in Seattle, WA (US). She has made significant strides in the field of immunotherapy, particularly focusing on B-cell related diseases. With a total of 2 patents to her name, her work is paving the way for new treatment options.

Latest Patents

Cecile's latest patents include groundbreaking innovations such as the "CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof." This patent provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, along with synergistic combination therapies of CD37-specific binding molecules with bifunctional chemotherapeutics like bendamustine. These therapies can be administered concurrently or sequentially to treat or prevent B-cell related autoimmune, inflammatory, or hyperproliferative diseases. Another notable patent is "CD37 immunotherapeutics and uses thereof," which shares similar innovative approaches to treating these conditions.

Career Highlights

Cecile Morales is currently associated with Emergent Product Development Seattle, LLC, where she continues to develop her innovative ideas. Her work is characterized by a commitment to advancing medical treatments and improving patient outcomes.

Collaborations

Cecile collaborates with talented individuals such as Philip Tan and Sandy Alexander Simon, contributing to a dynamic and innovative work environment.

Conclusion

Cecile Morales is a trailblazer in the field of immunotherapy, with her patents reflecting her dedication to addressing complex medical challenges. Her contributions are vital in the ongoing quest for effective treatments for B-cell related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…